<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080925</url>
  </required_header>
  <id_info>
    <org_study_id>040116</org_study_id>
    <secondary_id>04-C-0116</secondary_id>
    <secondary_id>CDR0000357432</secondary_id>
    <nct_id>NCT00080925</nct_id>
  </id_info>
  <brief_title>T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies</brief_title>
  <official_title>T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and&#xD;
      immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a&#xD;
      donor are rejected by the body's normal cells. Eliminating the T cells from the donor cells&#xD;
      before transplanting them and giving cyclosporine may prevent this from happening.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of T-cell-depleted allogeneic stem&#xD;
      cell transplantation after immunoablative induction chemotherapy and reduced-intensity&#xD;
      transplantation conditioning (chemotherapy) in treating patients with hematologic&#xD;
      malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine engraftment in patients with hematologic malignancies treated with&#xD;
           T-cell-depleted allogeneic stem cell transplantation after immunoablative induction&#xD;
           chemotherapy and reduced-intensity transplantation conditioning.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the incidence of acute graft-versus-host disease (GVHD), and nonrelapse&#xD;
           mortality (within 100 days after transplantation) in these patients.&#xD;
&#xD;
        -  Correlate levels of host immunosuppression before transplantation conditioning, as&#xD;
           evaluated by peripheral blood CD4 counts, with graft rejection/failure within 100 days&#xD;
           after transplantation and the level of donor hematopoietic chimerism 28 days after&#xD;
           transplantation in these patients.&#xD;
&#xD;
        -  Correlate donor-versus-recipient natural killer cell alloreactivity with graft&#xD;
           rejection/failure, acute GVHD, and relapse of malignant disease in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the development of allospecific cytotoxic T-lymphocytes after transplantation&#xD;
           in patients with myeloid or lymphoid leukemia.&#xD;
&#xD;
        -  Correlate serum interleukin-7 and interleukin-15 levels with in vivo changes in host&#xD;
           lymphocyte subpopulations in these patients during sequential immunoablative&#xD;
           chemotherapy, before allogeneic stem cell transplantation, and during immune&#xD;
           reconstitution after transplantation.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Induction chemotherapy: Patients receive 1 of 2 induction chemotherapy regimens&#xD;
           according to diagnosis. Patients with partial response or better after prior therapy&#xD;
           (i.e., already adequately immune depleted) proceed directly to the transplantation&#xD;
           preparative regimen.&#xD;
&#xD;
             -  Regimen A (Hodgkin's lymphoma, non-Hodgkin's lymphoma [except lymphoblastic&#xD;
                lymphoma], chronic lymphocytic leukemia, prolymphocytic leukemia, or multiple&#xD;
                myeloma): Patients receive rituximab IV (if they have CD20+ B-cell malignancies) on&#xD;
                day 1; fludarabine IV over 30 minutes on days 1-4; etoposide, doxorubicin, and&#xD;
                vincristine IV continuously on days 1-4; cyclophosphamide IV over 30 minutes on day&#xD;
                5; oral prednisone on days 1-5; and filgrastim (G-CSF) subcutaneously (SC)&#xD;
                beginning on day 6 and continuing until blood counts recover.&#xD;
&#xD;
             -  Regimen B (lymphoblastic lymphoma, acute myeloid leukemia, acute lymphoblastic&#xD;
                leukemia, refractory anemia with excess blasts, myeloproliferative disorders,&#xD;
                chronic myelomonocytic leukemia, or chronic myelogenous leukemia): Patients receive&#xD;
                G-CSF SC beginning 24 hours before initiating induction chemotherapy and continuing&#xD;
                until blood counts recover. Patients also receive fludarabine IV over 30 minutes&#xD;
                and cytarabine IV over 4 hours on days 1-5.&#xD;
&#xD;
      For both regimens, treatment repeats every 21 days for 1-2 courses. Patients who achieve&#xD;
      remission or who have responsive or stable disease after induction chemotherapy then proceed&#xD;
      to transplantation preparative regimen chemotherapy.&#xD;
&#xD;
        -  Transplantation preparative regimen chemotherapy: Patients receive fludarabine IV over&#xD;
           30 minutes and cyclophosphamide IV over 2 hours on days -6 to -3.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV over 2&#xD;
           hours twice daily beginning on day -1 and continuing IV or orally until day 100.&#xD;
           Patients with no acute GVHD at day 100 taper cyclosporine over 12 weeks.&#xD;
&#xD;
        -  Allogeneic stem cell transplantation (SCT): Patients undergo T-cell-depleted allogeneic&#xD;
           peripheral blood SCT on day 0. Patients receive G-CSF SC beginning on day 0 and&#xD;
           continuing until blood counts recover.&#xD;
&#xD;
        -  Donor lymphocyte infusion (DLI): Patients with persistent or progressive malignant&#xD;
           disease after transplantation or mixed chimerism that does not improve after tapering or&#xD;
           discontinuing immunosuppression therapy may receive DLI. DLI may be administered alone&#xD;
           or in combination with chemotherapy. DLI repeats every 4 weeks until adequate donor&#xD;
           chimerism is achieved or until GVHD develops.&#xD;
&#xD;
      Patients are followed at 28 and 100 days and then at 6, 9, 12, 18, and 24 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6-20 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>graft-versus-tumor induction therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following hematologic malignancies:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML), meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In first complete remission (CR1), meeting 1 of the following criteria:&#xD;
&#xD;
                         -  Adverse cytogenetics with minimal residual disease detectable by flow&#xD;
                            cytometry, cytogenetic analysis, fluorescence in situ hybridization&#xD;
                            (FISH), or polymerase chain reaction (PCR), defined as 1 of the&#xD;
                            following:&#xD;
&#xD;
                              -  Complex karyotype [≥ 3 abnormalities]&#xD;
&#xD;
                              -  inv(3) or t(3;3)&#xD;
&#xD;
                              -  t(6;9)&#xD;
&#xD;
                              -  t(6;11)&#xD;
&#xD;
                              -  Monosomy 7&#xD;
&#xD;
                              -  Trisomy 8, alone or with an abnormality other than t(8;21),&#xD;
                                 t(9;11), inv(16), or t(16;16)&#xD;
&#xD;
                              -  t(11;19) (q23;p13.1)&#xD;
&#xD;
                         -  Failed to achieve CR after primary induction chemotherapy&#xD;
&#xD;
                         -  Secondary AML&#xD;
&#xD;
                    -  In second or subsequent remission (CR2 or greater)&#xD;
&#xD;
               -  Acute lymphoblastic leukemia, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In CR1, meeting 1 of the following criteria:&#xD;
&#xD;
                         -  Adverse cytogenetics with minimal residual disease detectable by flow&#xD;
                            cytometry, cytogenetic analysis, FISH, or PCR, defined as the&#xD;
                            following:&#xD;
&#xD;
                              -  Translocations involving 11q23, t(9;22), or bcr-abl rearrangement&#xD;
&#xD;
                         -  Failed to achieve CR after primary induction chemotherapy&#xD;
&#xD;
                    -  In CR2, if CR1 was &lt; 12 months&#xD;
&#xD;
                    -  In CR3 or greater&#xD;
&#xD;
               -  Myelodysplastic syndromes (MDS)&#xD;
&#xD;
                    -  INT-2 or high-risk by International Prognostic Scoring System&#xD;
&#xD;
                    -  No MDS with Fanconi anemia&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML), meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Accelerated phase with treatment failure after imatinib mesylate&#xD;
&#xD;
                    -  Blast phase&#xD;
&#xD;
               -  Myeloproliferative disorders, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Agnogenic myeloid metaplasia with adverse-risk features, meeting at least 2&#xD;
                       of the following criteria:&#xD;
&#xD;
                         -  Hemoglobin &lt; 10 g/dL or &gt; 10g/dL if transfusion-dependent&#xD;
&#xD;
                         -  WBC &lt; 4,000/mm^3 OR &gt; 30,000/mm^3 OR requires cytoreductive therapy to&#xD;
                            maintain WBC &lt; 30,000/mm^3&#xD;
&#xD;
                         -  Abnormal cytogenetics, including +8, 12p-&#xD;
&#xD;
                    -  Polycythemia vera or essential thrombocythemia in transformation to&#xD;
                       secondary AML&#xD;
&#xD;
               -  Myelodysplastic/myeloproliferative disease&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia&#xD;
&#xD;
               -  Hodgkin's lymphoma or non-Hodgkin's lymphoma&#xD;
&#xD;
                    -  Refractory lymphoma with progressive disease during combination chemotherapy&#xD;
&#xD;
                    -  Relapse after OR ineligible for autologous stem cell transplantation (SCT)&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
                    -  Treatment failure* after fludarabine, chlorambucil, and at least 1 other&#xD;
                       salvage regimen&#xD;
&#xD;
               -  Prolymphocytic leukemia (PLL), meeting 1 of the following criteria:&#xD;
&#xD;
                    -  T-PLL&#xD;
&#xD;
                         -  Treatment failure* after alemtuzumab and at least 1 other regimen&#xD;
&#xD;
                    -  B-PLL&#xD;
&#xD;
                         -  Treatment failure* after fludarabine and at least 1 other salvage&#xD;
                            regimen&#xD;
&#xD;
               -  Multiple myeloma, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Relapse after autologous SCT&#xD;
&#xD;
                    -  Plasma cell leukemia&#xD;
&#xD;
                    -  Adverse cytogenetics, defined as 1 of the following:&#xD;
&#xD;
                         -  del(13q) = 11q translocation NOTE: *Treatment failure is defined as&#xD;
                            relapse within 6 months OR failure to achieve remission&#xD;
&#xD;
          -  Less than 10% blasts in bone marrow and no circulating blasts in peripheral blood for&#xD;
             the following diagnoses:&#xD;
&#xD;
               -  Primary or secondary leukemia&#xD;
&#xD;
               -  Refractory anemia with excess blasts&#xD;
&#xD;
               -  CML&#xD;
&#xD;
               -  Other eligible diagnosis in transformation to acute leukemia&#xD;
&#xD;
          -  Expected survival of approximately 1 year or less with conventional therapy&#xD;
&#xD;
          -  No active CNS involvement by malignancy*&#xD;
&#xD;
               -  Prior CNS involvement with no current evidence of CNS malignancy allowed NOTE:&#xD;
                  *Active CNS malignancy is defined by lymphoma: tumor mass on CT scan or&#xD;
                  leptomeningeal disease OR leukemia: blasts present on cerebrospinal fluid&#xD;
                  cytospin&#xD;
&#xD;
          -  Availability of a donor who is a sibling, parent, or offspring who shares 1 full&#xD;
             haplotype (HLA-A, -B, or -DR)&#xD;
&#xD;
               -  Recipient and donor must have at least a 2-antigen disparity in either the&#xD;
                  host-versus-graft or graft-versus-host direction&#xD;
&#xD;
               -  Parent or offspring donor who is mismatched for a single HLA antigen (i.e., 5/6&#xD;
                  HLA) is allowed&#xD;
&#xD;
               -  No sibling donor who is 6/6 HLA-matched OR mismatched for a single HLA antigen&#xD;
                  (i.e., 5/6 HLA)&#xD;
&#xD;
               -  No unrelated donor identified in a prior or current National Marrow Donor Program&#xD;
                  registry search&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 55&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count ≥ 20,0000/mm^3* (without transfusion) NOTE: *Lower values may be&#xD;
             accepted at the discretion of the principal investigator or study chairperson if due&#xD;
             to bone marrow involvement by malignancy&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  Bilirubin ≤ 2.5 times ULN*&#xD;
&#xD;
          -  Unconjugated hyperbilirubinemia consistent with Gilbert's syndrome allowed&#xD;
&#xD;
          -  No chronic active hepatitis B infection&#xD;
&#xD;
               -  Hepatitis B core antibody positive allowed provided patient is surface antigen&#xD;
                  negative and has no evidence of active infection&#xD;
&#xD;
          -  No hepatitis C viral infection&#xD;
&#xD;
               -  Seronegative for anti-hepatitis C antibody and detectable hepatitis C viral RNA&#xD;
                  by reverse transcriptase-polymerase chain reaction assay NOTE: *Higher levels may&#xD;
                  be accepted at the discretion of the principle investigator or study chairperson&#xD;
                  if such elevations are due to liver involvement by malignancy&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 45%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO ≥ 50% of expected value (corrected for blood hemoglobin level and alveolar&#xD;
             volume)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 year after study&#xD;
             participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection not responding to antimicrobial therapy&#xD;
&#xD;
          -  No psychiatric disorder that would preclude study compliance or informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior monoclonal antibody therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No administration of tyrosine kinase (TK) inhibitors, including imatinib mesylate and&#xD;
             dasatinib, during the conditioning regimen; TK inhibitor administration may resume 28&#xD;
             days after transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R. Bishop, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

